Get the Stockscreener App
0.4396
0.54%
-0.0024
After Hours:
.4495
0.0099
+2.25%
NeuBase Therapeutics Inc stock is currently priced at $0.4396, with a 24-hour trading volume of 72,166.
It has seen a -0.54% decreased in the last 24 hours and a -8.19% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.4397 pivot point. If it approaches the $0.4303 support level, significant changes may occur.
Previous Close:
$0.442
Open:
$0.43
24h Volume:
72,166
Market Cap:
$1.55M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-0.0371
EPS:
-11.84
Net Cash Flow:
$-14.85M
1W Performance:
+2.23%
1M Performance:
-8.19%
6M Performance:
-30.64%
1Y Performance:
+240.78%
1D Range:
$0.412
$0.45
52W Range:
$0.1282
$4.44
NeuBase Therapeutics Inc Stock (NBSE) Company Profile
Name
NeuBase Therapeutics Inc
Sector
Industry
Phone
412 763 3350
Address
350 Technology Drive, Suite 421, Pittsburgh, PA
NeuBase Therapeutics Inc Stock (NBSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-16-20 | Initiated | RBC Capital Mkts | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Nov-21-19 | Initiated | Oppenheimer | Outperform |
| Sep-24-19 | Initiated | BTIG Research | Buy |
View All
NeuBase Therapeutics Inc Stock (NBSE) Latest News
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
Benzinga
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Endeavor Group Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Benzinga
NeuBase Therapeutics Inc Stock (NBSE) Financials Data
NeuBase Therapeutics Inc (NBSE) Net Income 2024
NBSE net income (TTM) was -$13.73 million for the quarter ending September 30, 2023, a +59.35% increase year-over-year.
NeuBase Therapeutics Inc (NBSE) Cash Flow 2024
NBSE recorded a free cash flow (TTM) of -$14.85 million for the quarter ending September 30, 2023, a +49.65% increase year-over-year.
NeuBase Therapeutics Inc (NBSE) Earnings per Share 2024
NBSE earnings per share (TTM) was -$7.70 for the quarter ending September 30, 2023, a +62.98% growth year-over-year.
NeuBase Therapeutics Inc Stock (NBSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Symetryx Corp | 10% Owner |
Sep 11 '23 |
Sale |
1.44 |
3,376 |
4,861 |
472,926 |
| Symetryx Corp | 10% Owner |
Sep 08 '23 |
Sale |
1.53 |
128,847 |
197,136 |
476,302 |
| Symetryx Corp | 10% Owner |
Sep 07 '23 |
Sale |
1.80 |
74,852 |
134,734 |
605,149 |
| Symetryx Corp | 10% Owner |
Sep 01 '23 |
Buy |
0.98 |
61,076 |
59,732 |
680,081 |
| Stephan Dietrich A | Founder and CEO |
Aug 02 '23 |
Option Exercise |
0.02 |
93,234 |
2,051 |
93,234 |
About NeuBase Therapeutics Inc
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
1.53%
3.38%
Cap:
|
Volume (24h):